This combination was well tolerated and highly effective, with a much higher response rate (62 %) than expected with
pembrolizumab alone.
«I am treating people today with
pembrolizumab alone and seeing some impressive outcomes,» said Dr. Rosalyn Juergens, oncologist and site lead investigator at Hamilton Health Sciences» Juravinski Cancer Centre, and associate professor of oncology at McMaster University.
UNC Lineberger researchers are planning to launch an investigator - initiated clinical trial year to assess whether the combination denosumab with the checkpoint inhibitor pembrolizumab is more effective than
pembrolizumab alone for treating patients with advanced melanoma.
Not exact matches
Of those treated with
pembrolizumab and platinum + pemetrexed, the risk of death was reduced by 51 %, compared to those treated with platinum + pemetrexed
alone.
«The data show that treatment with
pembrolizumab and chemotherapy together is more effective than chemotherapy
alone,» says Gandhi.
Led by Leena Gandhi, MD, PhD, associate professor of medicine and director of thoracic medical oncology, researchers from the KEYNOTE - 021 study demonstrated for the first time that combining an immune checkpoint inhibitor — in this case,
pembrolizumab — with a platinum - doublet chemotherapy regimen might be more effective than chemotherapy
alone as first - line treatment for advanced, non-squamous NSCLC.